

**Maklumat tambahan indikasi untuk upload pada laman web**

**Year 2014**

**Products Approved For Additional Indication (DCA 277 – 7 Julai 2014)**

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	<p>1.1 <b>Trajenta Duo 2.5mg/500mg Film-Coated Tablets</b> [Linagliptin 2.5mg &amp; metformin hydrochloride 500mg]</p> <p>1.2 <b>Trajenta Duo 2.5mg/850mg Film-Coated Tablets</b> [ Linagliptin 2.5mg &amp; metformin hydrochloride 850mg ]</p> <p>1.3 <b>Trajenta Duo 2.5mg/1000mg Film-Coated Tablets</b> [Linagliptin 2.5mg &amp; metformin hydrochloride 1000mg]</p>	<p>➤ Indication:</p> <p><i>Trajenta Duo is indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin and metformin alone do not provide adequate glycaemic control.</i></p> <p>➤ Posology:</p> <p><u><i>For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin</i></u></p> <p><i>The dose of Trajenta Duo should provide linagliptin dosed at 2.5mg twice daily (5mg total daily dose) and a dose of metformin similar to the dose already being taken. When linagliptin plus metformin hydrochloride is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia.</i></p>	<p><b>BOEHRINGER INGELHEIM (MALAYSIA) SDN. BHD.</b> Suite 15-5, Level 15 Wisma UOA Damansara II No.6, Jalan Changkat Semantan, Damansara Heights, 50490 Kuala Lumpur</p>